Published in AIDS Weekly, September 29th, 1997
The soft-gel formulation, to be marketed as Fortovase, gave 10 times the exposure that current, hard-gel version of Invirase gives, Roche said in a statement. When given in triple-combination therapy, the drug helped lower blood levels of HIV to below detectable limits, scientists working with Roche told a meeting of the Infectious Disease Society of America.
They said they gave Fortovase along with the more standard drugs AZT and 3TC to 41...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.